With this seminar, and others planned, we want to facilitate an information-exchange and dialogue between investors, clinicians, and scientists that will promote a greater understanding of how cell therapies will shape the future of medicine.
Toronto, Canada & Kyriat Weizmann, Israel (PRWEB) October 31, 2013
Hemostemix Ltd. and BioForum have announced a jointly-sponsored symposium entitled “Cell Therapy – an evolving industry” to be held November 4 at the Dan Hotel in Tel Aviv, Israel.
The event will feature invited speakers including Dr. Elmar Burchardt, Pfizer’s Vice President of Regenerative Medicine and cell therapy executives from Canada, United States, India, and Israel. The seminar will brief attendees on global industry trends, discuss optimal cell therapy product development, review the impact of CROs on clinical trial outcomes, present key elements of cellular product analytics, outline cell therapy business models, and engage in an open dialogue about the potential keys to cell therapy being a pillar of future healthcare.
“We are pleased to play a role in hosting an event which highlights the global cell therapy industry,” stated Hemostemix President and founder, Dr. Valentin Fulga. “With this seminar, and others planned, we want to facilitate an information-exchange and dialogue between investors, clinicians, and scientists that will promote a greater understanding of how cell therapies will shape the future of medicine.”
“Bioforum is excited to provide what it believes will be an important and useful seminar in this exciting new field of science and medicine,” stated Yehudith Wexler, Chairperson of Bioforum.
For more information about the seminar, click here.
This seminar is part of a series of presentations intended to introduce the company and its platform technology to a wide audience in the context of the cell therapy industry’s progress and maturation. This includes a recent keynote presentation (“Synergetic Cell Population – a powerful tool for autologous therapies”) delivered October 23rd in Orlando, FL and an upcoming presentation (“A peripheral blood-derived cellular population can be differentiated into neural like progenitor cells”) at the TERMIS-AM 2013 Conference to be held November 10-13in Atlanta, Georgia.
About Hemostemix Ltd
Hemostemix Ltd is a Canadian-Israeli company developing and commercializing innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. For more information see http://www.hemostemix.com.
About Bioforum
Established in 1998, Bioforum provides a wide range of services in the areas of Education and Training, Clinical Data, Regulatory Submissions and Clinical Supply (inPACK). Bioforum's strategic lines of business combine professional services, process optimization, technology and education. Bioforum maximizes their costumers’ benefits by providing cost effective outsourcing and consultation services for the pharmaceutical, medical and medical device industries. For more information about Bioforum, see http://www.bioforum.co.il.
We're here to help.
Call 1-866-640-6397
©Copyright 1997-, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
